Ser1320

Site Information
HRtssGtsLSAMHSs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 476253

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 )
Disease tissue studied:	breast cancer ( 2 ) , leukemia ( 21 ) , chronic myelogenous leukemia ( 21 ) , lung cancer ( 1 , 7 ) , non-small cell lung cancer ( 7 ) , non-small cell lung adenocarcinoma ( 1 ) , pancreatic ductal adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 3 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 13 ) , 293 (epithelial) [AT1 (human), transfection] ( 12 ) , 293 (epithelial) ( 10 , 11 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 8 ) , Flp-In T-Rex-293 (epithelial) ( 8 ) , GM00130 (B lymphocyte) ( 14 ) , H2009 (pulmonary) ( 7 ) , H2077 (pulmonary) ( 7 ) , H2887 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC1359 (pulmonary) ( 7 ) , HCC2279 (pulmonary) ( 7 ) , HCC366 (pulmonary) ( 7 ) , HCC4006 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 7 ) , HEK293T (epithelial) ( 22 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HMLER ('stem, breast cancer') ( 2 ) , Jurkat (T lymphocyte) ( 5 , 15 ) , K562 (erythroid) ( 6 , 21 ) , LOU-NH91 (squamous) ( 7 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H1568 (pulmonary) ( 7 ) , NCI-H1650 (pulmonary) ( 16 , 17 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H2172 (pulmonary) ( 7 ) , NCI-H3255 (pulmonary) ( 18 , 19 , 20 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H647 (pulmonary) ( 7 ) , PC9 (pulmonary) ( 1 )

References
1	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
2	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
3	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
4	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
8	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
9	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
10	Mulhern D (2011) CST Curation Set: 12830; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
11	Mulhern D (2011) CST Curation Set: 12831; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
12	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
13	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
14	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
15	Possemato A (2009) CST Curation Set: 8352; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
16	Possemato A (2009) CST Curation Set: 8051; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
17	Possemato A (2009) CST Curation Set: 8050; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
18	Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
19	Possemato A (2009) CST Curation Set: 7394; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
20	Possemato A (2009) CST Curation Set: 7393; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
21	Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
22	Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204 17287340 Curated Info